Ramucirumab
Showing 1 - 25 of 163
Gastroesophageal Adenocarcinoma Trial (Paclitaxel, Ramucirumab, Zanidatamab)
Not yet recruiting
- Gastroesophageal Adenocarcinoma
- Paclitaxel
- +2 more
- (no location specified)
Sep 12, 2023
Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in Chuo Ku (TRK-950, Ramucirumab,
Not yet recruiting
- Gastric Adenocarcinoma
- +2 more
- TRK-950
- +2 more
-
Chuo Ku, JapanOsaka International Cancer Institute
Sep 14, 2023
Gastric Cancer, NSCLC, Colo-rectal Cancer Trial in Changchun (Ramucirumab Injection, Ramucirumab Injection [Cyramza])
Completed
- Gastric Cancer
- +2 more
- Ramucirumab Injection
- Ramucirumab Injection [Cyramza]
-
Changchun, Jilin, ChinaAffiliated Hospital of Changchun University of Traditional Chine
Mar 24, 2023
Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy Trial in Tianjin (Cadonilimab Injection, Ramucirumab
Recruiting
- Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy
- Cadonilimab Injection
- Ramucirumab Injection
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital Airport Hospital
May 14, 2023
Metastatic Gastric Adenocarcinoma, Second Line, Chemo Trial (nal-IRI /Experimental, Ramucirumab /Experimental,
Not yet recruiting
- Metastatic Gastric Adenocarcinoma
- +2 more
- nal-IRI /Experimental
- +2 more
- (no location specified)
Jun 25, 2023
Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint
Not yet recruiting
- Recurrent Head and Neck Cancer
- +5 more
- Ramucirumab
- Pembrolizumab
-
Saint Louis, MissouriWashington University School of Medicine
Jul 30, 2023
Non Small Cell Lung Cancer, Metastatic, Recurrent Trial in United States (Lorlatinib, Ramucirumab)
Recruiting
- Non Small Cell Lung Cancer
- +2 more
- Lorlatinib
- Ramucirumab
-
Middletown, New Jersey
- +5 more
Aug 17, 2023
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial (Ramucirumab, Paclitaxel)
No longer available
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Ramucirumab
- Paclitaxel
- (no location specified)
Jan 17, 2023
Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer Trial (T-Dxd(Trastuzmab deruxtecan), Ramucirumab)
Not yet recruiting
- Gastric Cancer
- Gastroesophageal Junction (GEJ) Cancer
- T-Dxd(Trastuzmab deruxtecan), Ramucirumab
- (no location specified)
Jun 7, 2023
Head and Neck Squamous Cell Carcinoma Trial in Saint Louis (drug, other, procedure)
Active, not recruiting
- Head and Neck Squamous Cell Carcinoma
- Ramucirumab
- +4 more
-
Saint Louis, MissouriWashington University School of Medicine
Dec 21, 2022
Gastric Adenocarcinoma Trial in Guangzhou (Sintilimab, Ramucirumab, Cisplatin)
Active, not recruiting
- Gastric Adenocarcinoma
- Sintilimab
- +5 more
-
Guangzhou, ChinaSun Yat-sen University Cancer Center
Oct 10, 2022
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (Chemotherapy, Pembrolizumab, Ramucirumab)
Not yet recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Chemotherapy
- +2 more
- (no location specified)
Jan 9, 2023
Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) Trial in Tianjin (Serplulimab+Paclitaxel+Apatinib,
Recruiting
- Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Jul 5, 2023
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, biological, drug)
Not yet recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Biospecimen Collection
- +5 more
- (no location specified)
Sep 7, 2023
Carcinoid Tumors Trial in Boston (Ramucirumab, Somatostatin Analog)
Active, not recruiting
- Carcinoid Tumors
- Ramucirumab
- Somatostatin Analog
-
Boston, Massachusetts
- +1 more
Apr 14, 2022
Gastric Cancer Trial in Seoul (pembrolizumab plus ramucirumab)
Recruiting
- Gastric Cancer
- pembrolizumab plus ramucirumab
-
Seoul, Korea, Republic of
- +1 more
Feb 23, 2022
Non Small Cell Lung Cancer Trial in Philadelphia (Nivolumab, Ramucirumab)
Recruiting
- Non Small Cell Lung Cancer
- Nivolumab
- Ramucirumab
-
Philadelphia, PennsylvaniaFox Chase Cancer Center
Apr 6, 2022
Transitional Cell Carcinoma Trial in New Haven (Pembrolizumab and Ramucirumab)
Withdrawn
- Transitional Cell Carcinoma
- Pembrolizumab and Ramucirumab
-
New Haven, ConnecticutYale University
Feb 18, 2022
Gastric Adenocarcinoma, Metastatic Adenocarcinoma of the Gastroesophageal Junction Trial in Germany (Ramucirumab, TAS 102)
Active, not recruiting
- Gastric Adenocarcinoma
- Metastatic Adenocarcinoma of the Gastroesophageal Junction
- Ramucirumab
- TAS 102
-
Frankfurt, Germany
- +4 more
Mar 2, 2022
Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial (Poziotinib
Not yet recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +3 more
- Poziotinib Hydrochloride
- 1429757-68-5, HM781-36B, NOV-1201 Hydrochloride, NOV120101 Hydrochloride, Poziotinib HCl, POZIOTINIB HYDROCHLORIDE
- (no location specified)
Jul 18, 2022
Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Stage III Gallbladder Cancer AJCC v7 Trial in Houston
Completed
- Cholangiocarcinoma
- +11 more
- Laboratory Biomarker Analysis
- Ramucirumab
-
Houston, TexasM D Anderson Cancer Center
Jul 7, 2022
NSCLC Trial in Philadelphia (Carboplatin, Paclitaxel, Ramucirumab)
Recruiting
- Non-small Cell Lung Cancer
- Carboplatin
- +2 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Mar 14, 2022
NSCLC Stage IB, NSCLC Stage II, NSCLC Stage ?A Trial in Kashiwa, Shinjuku-Ku (Pembrolizumab, Ramucirumab, Surgery)
Recruiting
- Non-small Cell Lung Cancer Stage IB
- +2 more
- Pembrolizumab
- +2 more
-
Kashiwa, Chiba, Japan
- +1 more
Apr 4, 2022
Malignant Solid Tumor Trial in United States (ramucirumab (IMC-1121B), paclitaxel)
Completed
- Malignant Solid Tumor
- ramucirumab (IMC-1121B)
- paclitaxel
-
Ann Arbor, Michigan
- +5 more
Feb 14, 2022
Tumors, Child, Adolescent Trial in Leiden (Ramucirumab, Cyclophosphamide, Vinorelbine)
Recruiting
- Neoplasms
- +2 more
- Ramucirumab
- +7 more
-
Leiden, NetherlandsLeids Universitair Medisch Centrum
Aug 14, 2023